Skip to main content

Table 2 Baseline characteristics in patients and GP controls without a previous history of NL, given as frequencies (%)

From: Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study

Comorbidities and medications at baseline Gout cases
(N = 29,171)
GP controls
(N = 131,449)
Age, mean (std) 69.1 (14.8) 68.2 (14.6)
Men (%) 67.3 66.3
Hypertension (%) 58.4 33.0
Ischemic heart disease (%) 26.6 13.5
Diabetes (%) 18.6 9.2
Kidney disease (%) 11.1 2.6
Obesitya (%) 9.9 3.1
Statins (%) 32.0 19.3
Allopurinol (%) 26.4 N/Ac
Beta blockers (%) 38.4 20.1
Calcium antagonists (%) 16.3 10.9
Thiazide diuretics (%) 6.1 3.6
Losartan (%) 4.0 2.0
Potassium-sparing diuretics (%) 6.7 2.1
RAAS-inhibitors (%) 24.9 12.2
Loop diuretics (%) 27.9 7.9
Education (≤9) years (ref)b (%) 44.7 41.0
Education (10‒12) yearsb (%) 37.8 36.9
Education (>12) yearsb (%) 15.5 20.3
  1. NL, nephrolithiasis, RAAS renin-angiotensin-aldosterone-system, N/A not applicable
  2. aBased on ICD-10-code E66 and ATC code A08
  3. bBaseline data were complete except for data on education level, which was missing for 1.8% of the GP controls and 2 percent of the gout cases.
  4. cPrior users of urate-lowering-therapy were excluded from the control group